Navigation Links
Second-most common breast cancer subtype may benefit from personalized treatment approach
Date:2/25/2014

PITTSBURGH, Feb. 26, 2014 The second-most common type of breast cancer is a very different disease than the most common and appears to be a good candidate for a personalized approach to treatment, according to a multidisciplinary team led by University of Pittsburgh Cancer Institute (UPCI) scientists.

Invasive lobular carcinoma, which is characterized by a unique growth pattern in breast tissue that fails to form a lump, has distinct genetic markers that indicate there may be benefits from drug therapies beyond those typically prescribed for the more common invasive ductal carcinoma. The results will be published in the March 1 issue of the journal Cancer Research.

Patients with invasive lobular carcinoma are typically treated through surgical removal of the cancer, followed by chemotherapy or hormone therapy or both, usually with the estrogen-mimicking drug tamoxifen or estrogen-lowering aromatase inhibitors, the same as patients with invasive ductal carcinoma.

"However, recent analyses have shown that a subset of patients with lobular carcinoma receive less benefit from adjuvant tamoxifen than patients with ductal carcinoma," said senior author Steffi Oesterreich, Ph.D., professor at UPCI, a partner with UPMC CancerCenter, and director of education at the Women's Cancer Research Center. "Our study, the largest of its kind, indicates an issue with the estrogen receptors inside lobular carcinoma cells and points to a potential target for drug therapy in future clinical trials, which we are developing."

The UPCI study, funded by the Breast Cancer Research Foundation and the U.S. Department of Defense, included collaborations across multiple disciplines, ranging from biostatistics and biomedical informatics to pathology and human genetics, in order to produce results with the potential for rapid translation into clinical therapies.

"In addition to its potential clinical implications, the study highlights the need for more and better models mimicking invasive lobular cancer that can be used for laboratory studies," said lead author Matthew Sikora, Ph.D., a postdoctoral associate at UPCI.

"Because lobular carcinomas account for only 10 to 15 percent of breast cancers, while ductal carcinomas make up nearly 80 percent, lobular carcinomas are a less attractive option for laboratory study," said Dr. Sikora. "However, 30,000 women in the U.S. are diagnosed with lobular carcinoma every year, so there is a great need for further study of this disease."


'/>"/>

Contact: Allison Hydzik
hydzikam@upmc.edu
412-647-9975
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert  

Related biology news :

1. Finding common ground fosters understanding of climate change
2. Common crop pesticides kill honeybee larvae in the hive
3. Arctic cyclones more common than previously thought
4. How common is aggression in UK dogs?
5. Walking the walk: What sharks, honeybees and humans have in common
6. Study of rodent family tree puts brakes on commonly held understanding of evolution
7. Human error most common cause of birth asphyxia
8. Gene linked to common intellectual disability
9. Model virus structure shows why theres no cure for common cold
10. Common bias known as the endowment effect not present in hunter-gatherer societies
11. OU research team finds a common bioindicator resistant to insecticides
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Second-most common breast cancer subtype may benefit from personalized treatment approach
(Date:12/16/2016)...   IdentyTechSolutions America LLC , a leading ... and a cutting-edge manufacturer of software and hardware ... seamless, integrated solutions that comprise IDT biometric readers ... provide IdentyTech,s customers with combined physical identification and ... and theft. "We are proud to ...
(Date:12/15/2016)... 2016   WaferGen Bio-systems, Inc. (NASDAQ: ... announced today that on December 13, 2016, it received ... Nasdaq Stock Market LLC which acknowledged that, as of ... common stock had been at $1.00 or greater for ... with Listing Rule 5550(a)(2) of the Nasdaq Stock Market. ...
(Date:12/15/2016)... , Dec. 14, 2016 "Increase in ... biometrics market" The mobile biometrics market is expected to ... 49.33 billion by 2022, at a CAGR of 29.3% ... factors such as the growing demand for smart devices, ... transactions. "Software component is expected to grow ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... ... January 18, 2017 , ... ... the CHI SCOPE Summit for Clinical Ops Executives (Hyatt Regency Miami, January 24-26). ... to examine vital clinical research issues such as trial performance metrics, patient enrollment ...
(Date:1/18/2017)... ... January 18, 2017 , ... uBiome, the leading ... by its Science Editor, Dr. Elisabeth Bik, in the December 2016 issue of ... joined uBiome in October 2016 from her previous position at Stanford University School ...
(Date:1/18/2017)... Shareholder rights law firm Johnson & Weaver, ... members of CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD ... proposed sale of the Company to Eli Lilly and ... molecules for the acute treatment of migraines. ... a definitive merger agreement with Eli Lilly. Under the ...
(Date:1/18/2017)... Jan. 18, 2017  Caris Life Sciences, a ... Foundation, the largest private funder of pancreatic cancer ... evaluating the impact of immunotherapy in the treatment ... enrollment services to identify potential trial candidates based ... treating physicians and study investigators. The Lustgarten Foundation ...
Breaking Biology Technology: